The European Commission concludes exploratory talks with CureVac (NASDAQ:CVAC) for a contractual framework to purchase as many as 225M COVID-19 vaccine doses, once proved to be safe and effective.
The Company made a successful U.S. debut on August 14, jumping out of the gate in its IPO at $44.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.